FDA approves Celgene’s bone marrow cancer treatment

(Reuters) – The U.S. Food and Drug Administration on Friday approved Celgene Corp’s Inrebic to treat certain rare forms of bone marrow cancer called myelofibrosis, making it the second approved drug to treat the disease. Inrebic belongs to a class of drugs kno... More »